DocumentsDate added
Original article
Bharani Kalpana R1 , Chandel Nitibhushansingh R2,*, Goyal Chhaya A3
Affiliation:-
1Post graduate Student (MD) of Department of Pharmacology, Sri Aurobindo Medical College & PG Institute, Indore, Madhya Pradesh, India
2Associate Professor, MD (Pharmacology), Department of Pharmacology, Sri Aurobindo Medical College & PG Institute, Indore, Madhya Pradesh, India
3Professor, MD (Pharmacology), Department of Pharmacology, Sri Aurobindo Medical College & PG Institute, Indore, Madhya Pradesh, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Pharmacology, Sri Aurobindo Medical College & PG Institute, Indore, Madhya Pradesh, India
*To whom it corresponds:-
Dr.Nitibhushansingh Chandel.
504, Adarsh, Sri Aurobindo Medical College & PG Institute, Indore-Ujjain road, Indore-453555(M.P)
Contact no: +91-8225033075
Abstract:
Aim: To evaluate occurrence of Dermatological manifestations of Adverse Drug Reactions in a Tertiary care hospital.
Material & Methods: It was cross sectional observational study of One-year duration. It included Patients of all ages and both sexes taking drugs of any category and attending Dermatology OPD or admitted to IPD for suspected dermatological manifestation of adverse drug reaction. Data was collected on CDSCO’s suspected adverse drug reaction reporting from and analyzed by doing causality assessment using WHO-UMC scale.
Observation & Results: Amongst 231 cases observed, oral Antimicrobials-41 (17.75%), Injectable Antimicrobials-40 (17.32%), NSAID’s-40 (17.32%.) and Topical Steroids (Betnovate)-36 (15.58 %.) were the leading cause.
Antiepileptics-18 (7.79%), Anti-cancer drugs-13 (5.63%), Blood and its products-12 (5.19%) and Topical clobetasol with Gentamicin-10 (4.33%), Oral Steroid-8(3.46%), Anti-tubercular drugs-8 (3.46%) and iron and multivitamins -5 (2.16%) were responsible for remaining cases.
Regarding the type of cutaneous drug reactions, 95 cases were of maculopapular rashes (41.12%), next being steroid damaged face in 42 (18.18%) followed by acute urticaria in 20 (8.65%) patients. Other reactions were fixed drug eruption in 18 (7.79%), Alopecia in 11 (4.76%) and Injection site redness and itching in 8 (3.46%) patients.
7 case were of Erythema multiforme constituting about (3.03%) of all cases, 4 of Stevens Johnson syndrome (1.73%), 3 each of facial swelling with itching (1.29%) and Acneform eruptions (1.29%).
Toxic epidermal necrolysis, angioedema and steroid induced purpura each were seen in 2 cases (0.86%).Steroid induced Cushing syndrome was also observed in 2 of the cases (0.86%).
Conclusion: Dermatological manifestation of adverse drug reaction is associated with variety of drugs, varies in severity and is easily noticeable by all patients. It precludes further use of that drug in these patients. Therefore, the impact can be significant in terms of cost and health service resources.
Keywords: Cutaneous adverse drug reaction; Pharmacovigilance.
REFERENCES
1.Wenchen K W, Nicholas P. Evaluation of outpatient Adverse Drug Reactions Leading to Hospitalization. American journal of Health- System Pharmacy.2003;60 (3): 253-259.
2.Borda, I.T., Slone, D., and Jick, H. Assessment of adverse reactions within a drug surveillance Program. J.A.M.A.205:645 (1968).
3.Ogilvie, H.I and Ruedy,J. Adverse drug reactions during hospitalization. Canad.med. Assoc.J.1967; 97:1450.
4.Babu K, Belgi G. management of Cutaneous drug reactions. Current Allergy and Asthma Reports. 2002; 2:26-33
5.Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, Cocci A, Moretti U , Velo G and Leone R. Cutaneous reactions to drugs. An analysis of Spontaneous reports in four Italian regions .Br J Clin Pharmacol 1999; 48: 839-846.
6.Stewart RB,May FE and Cullen SI. Dermatologic adverse drug reactions in Hospitalized Patients.Am J Hospitalized Patients. Am J Hosp Pharm 1979;36: 609-612.
7.Chatterejee S, Ghosh AP, Barbhuiya J, Dey SK. Adverse Cutaneous drug reactions: A one year survey at a dermatology outpatient clinic of tertiary care hospital. Indian journal of Pharmacology 2006; 38(6): 429-431.
8.Protocol for National Pharmacovigilance programme version 1; Central Drug standard Control organization. Directorate General of Health services, Ministry of Health & family Welfare, Govt. of India: Nov 2004.
9.Parthsarathi G, Gogtay N. Causality assessment of adverse drug reactions. Proceedings of the national Training Course on Pharmacovigilance: 2005 jan.17-21; Mumbai, India.
10.Inbaraj S.D., Muniappan M., Muthiah N.S. Pharmacovigilance of the Cutaneous Drug Reactions in Outpatients of Dermatology Department at a Tertiary Care Hospital .Journal of Clinical and Diagnostic Research. 2012;6(10): 1688-1691
11.Saha Abanti, Das Nilay Kanti, Hazra Avijit .Cutaneous adverse drug reaction profile in a tertiary care outpatient setting in Eastern India, Indian journal of Pharmacology 2012; 44; (6):792-797.
12.Sachin Hiware, Meena Shrivastava, Dharmendra Mishra. Evaluation of Cutaneous Drug Reactions in Patients Visiting Out Patient Departments of Indira Gandhi Government Medical College and Hospital (IGGMC and H), Nagpur.Indian journal of dermatology 2013; 58(1) 18-21
13.S.Ghosh, Leelavathi D, Acharya, Study and evaluation of the various cutaneous adverse drug reactions in kasturba hospital, manipal, Indian journal of pharmaceutical sciences, 2006; March-April:212-215.
Article citation:
Bharani Kalpana R,Chandel Nitibhushansingh R,Goyal Chhaya A. Dermatological manifestations of adverse Drug reactions: An observational study from tertiary care center of central India. J Pharm Biomed Sci 2014; 04(03): 208-214. Available at www.jpbms.info.
Source of support: Department of Dermatology & VD, Sri Aurobindo Medical College & PG Institute, Indore.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Bharani Kalpana R,Chandel Nitibhushansingh R,Goyal Chhaya A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Gautam Vijayendra B1 , Chandel Nitibhushansingh R2,*, Goyal Chhaya A3
Affiliation:-
1Post graduate Student (MD) of Department of Pharmacology, Sri Aurobindo. Medical College & PG Institute, Indore, Madhya Pradesh, India
2Associate Professor, MD (Pharmacology), Department of Pharmacology, Sri Aurobindo. Medical College & PG Institute, Indore, Madhya Pradesh, India
3Professor, MD (Pharmacology), Department of Pharmacology, Sri Aurobindo. Medical College & PG Institute, Indore, Madhya Pradesh, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Pharmacology, Sri Aurobindo Medical College & PG Institute, Indore, Madhya Pradesh, India
*To whom it corresponds:-
Dr.Nitibhushansingh Chandel.
504, Adarsh, Sri Aurobindo Medical College & PG Institute, Indore-Ujjain road, Indore-453555(M.P), India
Contact no: +91-8225033075+91-8225033075
Abstract
Aim: To evaluate & Compare analgesic activity of Potassium channel opener (nicorandil) with Gabapentin in animal models of Neuropathic Pain.
Material & Methods: Double distilled water (5 ml/kg, i.p), Nicorandil (1 mg/kg, i.p) & Gabapentin (50 mg/kg, i.p) was administered to Normal rats. Neuropathic Pain was induced by administering Vincristine (50µg/kg i.p.) Nicorandil (1 mg/kg, i.p) and Gabapentin (50 mg/kg, i.p) were administered to Neuropathic rats. Evaluation of analgesic activity was done using Hot Plate Method (HPM), cold Tail Immersion Test (TIT), and Acetone drop method (ADM) on days 2, 6, 8, &10.
Observation & results: The Mean ± SEM of Paw withdrawal latencies (PWL) in HPM and Tail withdrawal latencies (TWL) in TIT on 2nd, 6th, 8th & 10th Day in Normal rats was 9.085±1.836, 11.378±1.7852, 8.711±1.617, 12.442 ±1.817 seconds and 8.326±2.034, 5.77±1.879, 6.454±1.478, 8.413±1.949 seconds, respectively. DDW, Nicorandil did not produce any analgesia in Normal rats (P>0.05). Gabapentin produced analgesia in normal rats (P<0.05).The Mean ± SEM of PWL in HPM and TWL in TIT on 2nd, 6th, 8th & 10th Day in Vincristine treated (Neuropathic rats) was 8.7±1.359, 6.6±0.7333, 6.1±0.6403, 4.6±0.3399 seconds and 8.5±1.765, 5±0.7601, 4.3±0.4726, 3.4±0.4761 seconds, respectively; Gabapentin &, Nicorandil produced significant analgesia in neuropathic rats. (P<0.05).
The Mean ± SEM of PWL in ADM on 2nd, 6th, 8th & 10th Day in Normal rats was 1.2±0.2, 1.5±0.4014, 1.8±0.4667, 1±0.3333 scores and in Neuropathic rats was 5.4±0.67, 10.5±1.003, 11.1±1.32, 12.3±0.9434 scores, respectively. DDW, Gabapentin & Nicorandil did not alter these scores (P>0.05). Nicorandil, Gabapentin relieved cold Allodynia in neuropathic rats (P<0.05).
Conclusion: Nicorandil doesn’t have analgesic action in Normal rats. It has significant analgesic action in Heat Hyperalgesia and Cold Allodynia in Neuropathic rats. Analgesic action of Nicorandil is as good as that of Gabapentin in Neuropathic pain.
Keywords: Potassium Channel opener; Nicorandil; Neuropathic Pain; analgesic; Gabapentin.
REFERENCES
1.Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998;77:231–9.
2.Woolf CJ. Somatic pain-pathogenesis and prevention. Br J Anaesth 1995;75:169-176.
3.Woolf CJ. The pathophysiology of peripheral neuropathic pain-abnormal peripheral input and abnormal central processing. Acta Neurochir Suppl (Wien) 1993;58:122-130.
4.Lawson K. Potassium channel as targets for the management of pain. Cent Nerv Syst Agents Med Chem 2006;6:119-128.
5.Liss B, Roeper J. Molecular physiology of neuronal K-ATP channels (review). Mol Membr Biol 2001;18:117–127.
6.Ocana M, Del Pozo E, Barrios M, Robles LI, Baeyens JM. An ATP dependent potassium channel blocker antagonizes morphine analgesia. Eur J Pharmacol 1990;186:377–378.
7.Ocana M, Baeyens JM. Differential effects of K+ channel blockers on antinociception induced by alpha 2-adrenoceptor, GABAB and kappa-opioid receptor agonists. Br J Pharmacol 1993;110:1049–1054.
8.Robles LI, Barrios M, Del Pozo E, Dordal A, Baeyens JM. Effects of K+ channel blockers and openers on antinociception induced by agonists of 5 HT1A receptors. Eur J Pharmacol 1996;295:181–188.
9.Rodrigues AR, Duarte ID. The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K(+) channels. Br J Pharmacol 2000;129:110–114.
10.Alves DP, Soares AC, Francischi JN, Castro MS, Perez AC, Duarte ID. Additive antinociceptive effect of the combination of diazoxide, an activator of ATPsensitive K+ channels, and sodium nitroprusside and dibutyryl-cGMP. Eur J Pharmacol 2004;489:59–65.
11.Gottrup H, Juhl G, Kristensen AD. Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgaesia. Anesthesiology 2004;101:1400–8.
12.Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229–236.
13.Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9–17.
14.Pizziketti RJ, Pressnan NS, Geller EB, CowanA, Adler MW. Rat cold water tail flick: a novel analgesic test that distinguishes opioids agonists from mixed agonist-antagonists. Eur J Pharmacol 1985;119:23-9.
15.Siau C, Bennett GJ. Dysregulation of neuronal calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 2006;102:1485-1490.
16.Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994;59:369-376
17.Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004;109:150–161.
18.Jain V, Jaggi AS, Singh N. Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats. Pharmacol Res 2009;59(6):385-392.
19.Necker R, Hellon RF. Noxious thermal input from the rat tail: modulation by descending inhibitory influences. Pain 1978;4:231-242.
20.Yamazumi I, Okuda T, Koga Y. Involvement of Potassium Channels in Spinal Antinociceptions Induced by Fentanyl, Clonidine and Bethanechol in Rats. Jpn J Pharmacol 2001;87:268–276.
21.Asano T, Dohi S, Iida H. Antinociceptive action of epidural K+ ATP channel openers via interaction with morphine and and α2 adrenergic agonist in rats. Anesth Analg 2000;90:1146–1151.
22.Narita M, Takamori K, Kawashima N, Funada M, Kamei J, Suzuki T, et al. Activation of central ATPsensitive potassium channels produces the antinociception and spinal noradrenaline turnover-enhancing effect in mice. Psychopharmacology (Berl) 1993;113:11–14.
23.Welch SP, Dunlow LD. Antinociceptive activity of intrathecally administered potassium channel openers and opioid agonists: a common mechanism of action? J Pharmacol Exp Ther 1993;267:390–399.
24.Wu XF, Liu WT, Liu YP, Huang ZJ, Zhang YK, Song XJ. Reopening of ATP-sensitive potassium channels reduces neuropathic pain and regulates astroglial gap junctions in the rat spinal cord. Pain 2011;152(11):2605-2615.
25.Omar ME, Abdel-Salam, Amany A. Sleem Study of the analgesic, anti-inflammatory, and gastric effects of Gabapentin. Drug Discov Ther 2009;3(1):18-26.
26.Luszczki JJ, Koacz A, Wojdal E, Czuczwar M, Przesmycki K, Czuczwar SJ. Synergistic interaction of gabapentin with tiagabine in the hot-plate test in mice:an isobolographic analysis. Pharmacological Reports 2009;61:459-467.
27.Hahm TS, Ahn HJ, Bae CD, Kim HS, Lim SW, Cho HS, et al. Protective Effects of Gabapentin on Allodynia and α2δ1-Subunit of Voltage-dependent Calcium Channel in Spinal Nerve-Ligated Rats. J Korean Med Sci 2009;24:146-51.
28.Miyazaki R, Yamamoto T. Pain Mechanisms; The Efficacy of Morphine, Pregabalin, Gabapentin, and Duloxetine on Mechanical Allodynia Is Different from That on Neuroma Pain in the Rat Neuropathic Pain Model. Anesth Analg 2012;115:182–8.
29.Cheng JK, Pan HL, Eisenach JC. Antiallodynic Effect of Intrathecal Gabapentin and Its Interaction with Cbnidine in a Rat Model of Postoperative Pain. Anesthesiology 2000;92:1126-31.
30.Xiao WH, Bennett GJ. Gabapentin has an antinociceptive effect mediated via a spinal site of action in a rat model of painful peripheral neuropathy. Analgesia 1996;2:267–273.
31.Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, et al. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997;324:153–160.
32.Hwang JH, Yaksh TL. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically-induced neuropathic pain model in the rat. Reg Anesth 1997;22:249–256.
Article citation:
Gautam Vijayendra B, Chandel Nitibhushansingh R, Goyal Chhaya A. Comparative study of analgesic activity of Potassium channel opener with Gabapentin in animal models of neuropathic pain. J Pharm Biomed Sci 2014; 04(03): 226-234. Available at www.jpbms.info.
Source of support: Department of Dermatology & VD, Sri Aurobindo Medical College & PG Institute, Indore.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Gautam Vijayendra B, Chandel Nitibhushansingh R, Goyal Chhaya A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original Article
Rajinderjit Singh Ahi1,*, Asha Sharma2
Affiliation:-
1Associate Professor (MD Biochemistry), 2Demonstrator (MSc Biochemistry), Department of Biochemistry, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Biochemistry, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India
*To whom it corresponds:-
Dr.Rajinderjit Singh Ahi. (MD Biochemistry)
Associate Professor, Department of Biochemistry, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India
Abstract:
Background: CRP and Glycosylated haemoglobin are useful indicator in diagnosis and assessing the severity of type II Diabetes Mellitus (DM).
Aim: To study the effect of diabetes mellitus on the levels of Glycosylated haemoglobin and CRP.
Material and Methods: The study was conducted on 25 healthy control (Group-I), 20 uncontrolled type 2 diabetic subjects (Group-II) and 20 controlled type-2 diabetic subjects (Group-III).The levels of GHb and CRP were compared between healthy controls, controlled diabetes and uncontrolled diabetes.
Observation and Results: The rise in the level of GHb and CRP between healthy controls and uncontrolled diabetes and between controlled and uncontrolled diabetes cases was highly significant. The increase in Glycosylated hemoglobin (GHb) was statistically highly significant (t = 8.941, P < 0.001) in uncontrolled diabetic subjects when compared with healthy control subjects and also highly significant (t = 7.165, P < 0.001) when compared with controlled diabetic subjects. CRP level showed highly significant increase (t = 5.556, P < 0.001) in uncontrolled diabetic subjects in comparison to healthy control subjects and it also showed highly significant increase (t = 3.746, P < 0.001) when compared with controlled diabetic subjects.
Statistical analysis: The statistical analysis was carried out by the Students t- test.
Conclusion: It is concluded from this study that there is highly significant correlation between GHb, CRP and diabetes mellitus and these parameters increases with the severity of disease.
Keywords: Diabetes mellitus; C-Reactive protein; Gycosylated haemoglobin; Glucose.
REFERENCES
1.Gupta OP et al. In diabetes mellitus in developing countries, J.S. Bajaj, et al. Interprint, New Delhi (1999).
2.Hansson GK: Inflammation, atherosclerosis and coronary artery disease. N. Engl. J. Med. 2005; 352; 1685-1695.
3.Vu JD, Vu JB, Pio JR, Malik S, Franklin SS, Chen RS, Wong ND. Impact of C-reactive protein on the likelihood of peripheral arterial disease in US adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol 2005;96: 655-658.
4.Blake GJ, Ridker PM. CRP and other inflammatory risk markers in acute coronary syndrome. J. Am. Coll Cardiol. 2003; 41(4 Suppl. 5): 375-425.
5.Ridker PM. Clinical application of CRP for cardiovascular disease detection mand prevention. Circulation 2003; 107: 363-369.
6.Pradhan AD, Manson JE, Rifai N, Burning JE, Ridker PM. CRP interleukin 6, and risk of developing type-2 diabetes mellitus. JAMA 2001; 286: 327-334.
7.Trinder P: Determination of blood glucose using an oxidase-peroxidase system with a non carcinogenic chromogen. J.Clin.Path; 1969:22(2): 158-161.
8.Gonen B. Glycosylated hemoglobin. Diabetologia 1978; 15: 1.
9.Lars-olof Hanson et al: Current opinion in infectious diseases. 1997; 10: 196-201.
10.Uwe Kobold, Jan Olof, Jep and Son, Thomos Dulffur, Andreas Finke, Wieland Hoelzel and Kor Meidma. Candidate reference method for HbA1 based on peptide mapping; Clin Chem 1997; 43(10).
11.Freeman DJ, Norrie J, Caslake MJ, Gaw A, Lowe GD, O’Reilly DS, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-600.
12.Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands, EJ, et al: Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007; 56: 872- 878.
13.Jie Lin et al. Association between C-reactive protein and pre-diabetic status in Chinese Han clinical population. Diabetes / Metabolism Research and Reviews. 2009;25(3): 219-223.
14.Belfki et al. Bucolo G. and David H: Quantitative determination of serum triglyceride by: Association between C-reactive protein and type 2 diabetes in a Tunisian population. Inflammation. 2012; 35(2):684-9.
15.Swift DL, Johannsen NM, Earnest CP, Blair SN, Church TS. Effect of exercise training modality on C-reactive protein in type 2 diabetes. Med Sci Sports Exerc. 2012;44(6):1028-34.
16.Abbas Dehghan, Mandy van Hoek,Eric J.G. Sijbrands,Theo Stijnen,Albert Hofman, and Jacqueline C.M. Witteman. Risk of Type 2 Diabetes Attributable to C-Reactive Protein and Other Risk Factors. Diabetes care 2007; 30(10): 2695-2699.
Article citation:
Rajinderjit Singh Ahi, Asha Sharma. C-Reactive protein and glycosylated haemoglobin levels in Type II diabetes mellitus. J Pharm Biomed Sci 2014; 04(03): 222-225. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Rajinderjit Singh Ahi, Asha Sharma. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:
M. Anil Kumar1, Ch.Rohini2, E.Prabhakar Reddy3,*, V Siva Kumar4 ,P.V.L.N.Srinivasa Rao5
Affiliation:-
1Tutor,Department of Biochemistry, Pondicherry Institute of Medical Sciences Pondicherry,India
2Tutor, Department of Physiology, Sri Manakula Vinayagar Medical College and Hospital Pondicherry, India
3Associate Professor, Department of Biochemistry, Sri Lakshmi Narayana Institute of Medical Sciences Pondicherry, India
4Professor & Head, Department of Nephrology, Sri Venkateswara Institute of Medical Sciences, Tirupati, A.P, India
5Professor & Head, Department of Biochemistry, Sri Venkateswara Institute of Medical Sciences, Tirupati, A.P, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Biochemistry, Pondicherry Institute of Medical Sciences Pondicherry,India
*To whom it corresponds:-
M. Anil Kumar.
Department of Biochemistry,
Pondicherry Institute of Medical Sciences,
Pondicherry, India.
Abstract
Uremic malnutrition is predominantly present in patients with chronic kidney disease (CKD) and worsens with the progression of CKD and is more evident in stage 5 CKD. These patients have well-defined abnormalities in their plasma and to a lesser extent in their muscle amino acid profiles. Of these the plasma levels of branched chain aminoacids (BCAA) leucine, isoleucine and valine are particularly important in skeletal muscle energy metabolism, and leucine enhances protein synthesis. The nutritional status in predialysis patients is a predictor for their prognosis in the first period of dialysis. Serum albumin is the most commonly used nutritional marker however its serum concentration decreases sharply in response to inflammation. Plasma BCAA’s were evaluated along with albumin and C-reactive protein in fifteen patients of early stages of chronic kidney disease (stages I & II classified as per K/DOQI guidelines) and fifteen age and sex matched healthy controls. A significant decrease in plasma concentration of valine, leucine, and albumin, were observed in the study group when compared to the controls (p< 0.05). No significant difference in the CRP levels was observed between the two groups. Malnutrition seen in our patients point to the need to evaluate the nutritional status of CKD patients in the early stage and institution of measures in the form of amino acid supplementation in the early stages to decrease the morbidity and mortality in these patients before start of dialysis.
Keywords: Malnutrition; Predialysis; Albumin; C-reactive protein; Amino acid.
REFERENCES
1.Lara B. Pupim, Lilian Cuppari and Alp Ikizler. T: Nutrition and Metabolism in Kidney disease. Seminars in Nephrology 2006;26:134-157.
2.Kopple J D: Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994;24:1002-1009.
3.Kaysen GA, Rathore V, Shearer GC: Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney 1995.48:510-516.
4.Goldwasser P, Mittman M, Antignani A: Predictors of mortality on hemodialysis. J Am Soc Nephrology 1993;3:1613-1622.
5.Alp Ikizler.T. Nutrition and Kidney disease. In text book of Primer on Kidney Disease 4th ed, edited by Arthur Greenberg MD, Publishers: National Kidney Foundation Elesiver Saunders; Chapter. 63,495-499.
6.Matthews D, Fong Y: Aminoacid and protein metabolism, in Clinical Nutrition. Parenteral Nutrition, edited by Rombeau J, Caldwell M, Philadelphia, W .B. Saunders 1993:75-112.
7.YOUNG GA, SWANEPOEL CR, CROFT MR, HOBSON SM, PARSONS FM.Anthropometry and plasma valine, amino acids and nutrtional assessment of hemodialysis patients. Kidney Int 1982;21:492– 499.
8.Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergström J.Factors predicting malnutrition in hemodialysis patients: a cross-sectional study.Kidney Int. 1998 Mar; 53(3):773-82.
9.http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p4_classg1.html NKF K/DOQI guidelines.
10.Rajendra. W: High performance liquid chromatographic determination of aminoacids in biological samples by precolumn derivatization with O-Phthaldialdehyde. Journal of liquid chromatography 1987;10(5):941-955.
11.Ceballos I, Chauveau P, Guerin V, Bardet J, Parvy P, Jungers P: Early alterations of plasma free amino acids in chronic renal failure. Clin Chim Acta 1990;188(2):101-108.
12.Suvanapha R, Tungsanga K, Laorpatanaskul S, Sitprija V, Suwan S: Plasma aminoacid patterns in normal Thais and in patients with chronic renal failure. Journal of Med Assoc Thai.1991;74(4):211-217.
13.Hong SY, Yang DH, Chang SK: The relationship between plasma homocysteine and amino acid concentrations in patients with end-stage renal disease. Journal of Renal Nutrition 1998;8(1):34-39.
14.Sanz A, Lou LM, Salazar I, Perez J, Albero R, Paul J, et,al. Nutritional status and plasma aminoacid levels in hemodialysis. Nutr Hosp 1995 Nov-Dec; 10(6):348-353.
15.Bergström J, Fürst P, Norée LO, Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol 1974;36:693– 697.
16.Alvestrand A, Furst P, Bergstrom J: Intracellular aminoacids in uremia. Kidney International Supplement. 1983;24:S9-S16.
17.Noel J.M Cano, Denis Fouque and Xavier M. Leverve: Branced -chain Aminoacid: Metabolism, Physiology Function, and Application: Session IV. American Society for Nutrition J. Nutr 2006;136: 299S-307S.
18.P. Ivarsen, I.N. Tietze, E.B. Pedersen. Nutritional Status and Amino Acids in Granulocytes and Plasma in Patients with Chronic Renal Disease and Varying Residual Renal Function. Nephron 2001;88:224-232.
19.Duenhas MR, Draib SA, Avesani CM: Influence of renal function on spontaneous dietary intake and on nutritional status of chronic renal insufficiency patients. Eur J Clin Nutr 2003;57:1473-1478.
20.Khan IH, Catto GR, Edward N: Death during the first 90 days of dialysis: A case control study. Am J Kidney Dis 1995;25:276-280.
21. Lara B. Pupim, Lilian Cuppari, and T. Alp Ikizler: Nutrition and Metabolism in Kidney Disease. j.sem nephrol 2005; 09:134-157.
22. Robert Thomas, Abbas Kanso, and John R. Sedor: Chronic Kidney Disease and Its Complications. Prim Care 2008;35(2):329.
Article citation:
M.Anil Kumar, Ch.Rohini, E.Prabhakar Reddy, V Siva Kumar ,P.V.L.N.Srinivasa Rao. Branched Chain Amino Acid Profile In Chronic Kidney Disease Patients. J Pharm Biomed Sci 2014; 04(03): 256-260. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 M.Anil Kumar, Ch.Rohini, E.Prabhakar Reddy, V Siva Kumar, P.V.L.N.Srinivasa Rao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original Article
Bansal Vinita A1,Bansal Sangeeta A2,*
Affiliation:-
1Associated Professor, Department of Obstrectic and Gynecology, Index Medical College and Research Centre Indore, Madhya Pradesh, India.
2Associated Professor, Department of Anesthesiology, Index Medical College and Research Centre Indore, Madhya Pradesh, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Obstrectics and Gynecology, Index Medical College and Research Centre Indore, M.P, India.
*To whom it corresponds:-
Dr. Sangeeta Bansal-Agarwal
401, Gold Residency, 7/2 Manoramaganj, Indore- 452001, India
Mobile – 98260-15819
Abstract
Background: Aim of the study was to find out the types of brain lesions in eclampsia and the region most affected in brain using CT scan, so that neuro patho physiological changes can be co-related with clinical symptoms and be treated accordingly.
Method: Twenty five cases of eclampsia were selected randomly from patients who were admitted to antenatal ward or as emergency cases in labour room irrespective of age and parity and CT scan done.
Result: Twenty out of twenty five patients show positive CT scan finding most common being vasogenic oedema followed by venous infarct and hypertensive ischemic encephalopathy.
Conclusion: CT scan shows that 80 % patient had positive findings and most common region affected is parieto occipital lobes. The findings correlated well with clinical findings in eclampsia patients and treatment given accordingly leads to relief of the neurological symptoms and reversal of changes in fundus and repeat CT scan.
Keywords: CT scan; Eclampsia; Neurological changes.
REFERENCES
1.American College of Obstetricians and Gynaecologists. Management of pre-eclampsia. Technical Bulletin number.91, Washington DC. Feb 1991.
2.Barton JR, sibai BM. Cerebral pathology in eclampsia .clinperinatol 1991; 18:891-910.
3.Roberts JM, Redman CWG : Pre-eclampsia - more than. Pregnancy induced hypertension. Lancet 1993; 341: 1447-1451.
4.Redman CWG. Eclampsia still kills .Br Med J 1988; 296: 1209-10.
5.Richards A, Graham D, bullock R. Clinico pathological study of neurological complications due to hypertensive disorders of pregnancy. JneurolNeurosurg Psychiatry 1988;51:416-21.
6.Chester EM, Agamanolis D P, Bunker B Q, Victor M, hypertensive encephalopathy: a clinic pathologic study of 20 cases neurology 1978;28:928-39.
7.Weingarten KL, Zimmerman RO, Pinto RS, Whelan MA. Computed tomographic changes of hypertensive encephalopathy AJNR Am J Neuro radial 1985;6:395-8.
8.Rail Dl ,Perkin GD Computerizssed tomographic appearance of hypertensive encephalopathy. Archneurol 1980;37:310-1.
9.Royburt M, Seidman D S, Serr D M, Mashiach S. neurologic involvement in hypertensive disease of pregnancy. Obstet-Gynecolsurv 1991; 46:656-64.
10.Will AD, Lewis LK, Hinshaw D B, jr ,et al. Cerebral vasoconstriction in toxaemia Neurology 1987;37:1555-7.
11.Leitch CR, Cameron AD, Walker JJ : The changing pattern of eclampsia over a 60 years period. Br J Obstet Gynecol1997; 104 : 917- 922.
12.StrandgaardS : The lower and upper limits for autoregulation of cerebral blood flow. Stroke 1973; 4 : 323.
13.Benedetti TJ, QuilliganEJ : Cerebral oedema in severe pregnancy- induced hypertension. Am J ObstetGynecol 1980; 137: 860.
14.Will AD, Lewis KL, Hinshaw DB et al : Cerebralvasoconstriction in toxaemia. Neurology 1987; 37 : 1555-1557.
15.Qurashi AI, Frankel MR, Ottenlips JR et al : Cerebral haemodynamics in pre-eclampsia and eclampsia. ArchNeurol 1996;53:1226-1231 .
16.Gant NF. Daley GL, Chand S et al: A study of angiotensin II. Pressure response throughout primigravida pregnancy. JClin Invest 1973; 52: 2682.
17.Sibai BM, Schnneider JM, Morrison JC et al : The late postpartum eclampsia controversy. ObstetGynaecol 1980; 55:75-78.
18.Donaldson JO : Eclampsia. In: Neurology of pregnancy. W B Saunders. Philadelphia. 1989; 269-310.
19.Gyr T, Tamzin MS, ZimmerliW : Postpartum amaurosis in patients with pre-eclampsia. Z Geburzhilfe. Perinatal 1983; 187: 293-295.
20.HauswaldM : Cortical blindness and late postpartum eclampsia. Am J Emerg Med 1987; 5 : 130-132.
21.Beal MF, Chapman PH: Cortical blindness and homonymous hemianopia in postpartum period. JAMA 1980; 244: 2085-2087.
22.Arulkumaran S, Gibb DMF, Rouff M et al : Transient blindness associated with pregnancy induced hypertension. Br J ObstetGynaecol 1985; 92 : 847-849.
23.Beeson JH, DudoEE : Computed axial tomography scan demonstration of cerebral oedema in eclampsia preceded by blindness. ObstetGynecol 1982; 60 : 529-532.
Article citation:
Bansal Vinita A,Bansal Sangeeta A. Brain lesion in Eclampsia. J Pharm Biomed Sci 2014; 04(03): 241-245. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Bansal Vinita A, Bansal Sangeeta A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.